Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Abstract Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report the interim safety, tolerability, and efficacy of tofacitinib in PsA patients in OPAL Balance, a 3-year, open-label, long-term extension study (data cut-off: August 2017; dat...

Descripción completa

Detalles Bibliográficos

Autores principales:	Peter Nash, Laura C. Coates, Alan J. Kivitz, Philip J. Mease, Dafna D. Gladman, José A. Covarrubias-Cobos, Oliver FitzGerald, Dona Fleishaker, Cunshan Wang, Joseph Wu, Ming-Ann Hsu, Sujatha Menon, Lara Fallon, Ana Belén Romero, Keith S. Kanik
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Adis, Springer Healthcare 2020-06-01
Colección:	Rheumatology and Therapy
Materias:	Long-term extension Psoriatic arthritis Tofacitinib
Acceso en línea:	https://doi.org/10.1007/s40744-020-00209-4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!